ImmunoGen has significantly advanced with respect to mirvetuximab soravtansine. In April, the company announced positive interim data from a phase III study (FORWARD I), evaluating the candidate as a single-agent therapy for treating patients with platinum-resistant ovarian cancer, whose tumors express high or medium levels of FR alpha. Enrollment in the study was completed two months ahead of schedule and top-line data is expected during the first half of 2019.